Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-12-14 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase through centralized bidding on the Shanghai Stock Exchange. It details the number of shares repurchased, prices, total funds used, and references the board's approval of the repurchase plan. The document is short (1336 characters) and focuses on the share buyback activity rather than financial results or reports. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2022-12-14 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东集中竞价减持股份时间过半的进展公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the progress of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares held, shares reduced through centralized bidding, and the timeline of the reduction plan. The document includes tables with shareholding percentages and reduction amounts, and it explicitly states that the reduction plan is ongoing and has passed its halfway point. This type of document is a notification about changes in major shareholding levels, specifically a progress update on a significant shareholder's reduction of shares. It does not contain financial statements, audit information, or other report types. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming it is not a full report or announcement of a report publication.
2022-12-07 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It includes details about the product, its intended use, registration certificate number, and the impact on the company. The document is short (895 characters) and does not contain financial statements or detailed financial analysis. It is an announcement of a regulatory approval related to product registration, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-01 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the pledgee, pledge dates, and the proportion of shares pledged relative to total holdings and company stock. There is no financial statement, earnings data, or management discussion. The document is a disclosure about a shareholder's share pledge, which fits the category of Major Shareholding Notification (MRQ) as it involves significant share ownership and related changes.
2022-12-01 Chinese
圣湘生物科技股份有限公司关于2022年季度权益分派实施后调整回购股份价格上限暨回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the adjustment of the upper limit price for share repurchases following a quarterly dividend distribution in 2022. It details the board's approval of the share repurchase plan, the reasons for adjusting the repurchase price limit due to dividend distribution, and the progress of the repurchase as of November 30, 2022. The content focuses on share buyback activities, including price limits, repurchase amounts, and regulatory compliance disclosures. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. This fits the definition of a Transaction in Own Shares (POS) filing, which covers announcements about share repurchases or issuances by the company.
2022-12-01 Chinese
圣湘生物科技股份有限公司监事会关于2021年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the Supervisory Board regarding the first vesting list of a 2021 restricted stock incentive plan. It references relevant laws and regulations and confirms the eligibility and conditions of the incentive recipients. This is a regulatory compliance and internal verification statement related to stock incentive plans, not a full financial report, earnings release, or management discussion. It does not announce voting results, changes in management, or capital changes. It is a formal regulatory filing related to corporate governance and compliance disclosures but does not fit into more specific categories like Remuneration Information or Share Issue. Given the nature and length, it best fits the Regulatory Filings (RNS) category as a compliance disclosure document.
2022-11-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.